Focus on the journey, not the destination. Joy is found not in finishing an activity  but in doing it.

**Sign -up on our FREE daily newsletter of Morning Briefing, Market Recap + Educational Chart set-up, to get this directly in your email, please make sure to add our email address in your contact list, to ensure that it will get directly in your inbox, some email server directs our newsletter in Spam or Promotion folder. Thank you!**


** At the time of this writing, IBB -22% ytd performance ($265).**

These small cap biotech names have doubled/ >+100% return this year.

  • EXEL +164% ytd, rallies on its Cabozantinib drug for renal cell carcinoma .
  • We have publish an article on EXEL before the pop. Dec 2015, 1 year ago the article was published when it was at 4.75.

  • CLCD + 340% ytd.  Rallies on positive result of Phase 3 Samurai study.
  • AKAO +131% ytd. Rallies on positive date result of Phase 3 cUTI, CRE trials.

  • CRBP +421% ytd. This has been quietly moving on early summer, and before announcement Ph 2 result of Resunab.
  • Notable bearish article from Adam Feuerstein